insiderwall
Menu
SuperinvestorInsider
Sarepta Therapeutics Inc. SRPT

Super Investor & Insider

Nessuna transazione insider negli ultimi 6 mesi.

Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.

About

Sarepta Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and marketing therapies for rare diseases, with a strong emphasis on genetic and neuromuscular disorders. The company’s current portfolio includes approved treatments for Duchenne muscular dystrophy, alongside research progr

SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees835
TickerSRPT

Statistics

Market Cap$1.79B
Revenue (TTM)$2.20B
Net Income-$713.4M
Net Margin-32.5%
EPS$-7.13
P/E43.74
P/S0.74
P/B1.07
EV/EBITDA43.53
ROE4.9%
Dividend Yield
Price$16.91

Data: Twelve Data · Revenue = mcap / P/S